Inhibitors of Gut Bacterial l -Dopa Decarboxylation with Reduced Susceptibility to Host Metabolism

Microorganisms in the human gut influence the efficacy and metabolism of host-targeted small molecule therapeutics, including the frontline Parkinson's disease drug levodopa (l-dopa). Previous work has identified a mechanism-based inhibitor of gut bacterial decarboxylases that degrade l-dopa, α-fluoromethyltyrosine (AFMT). However, early experiments with AFMT in rodent models suggested undesirable in vivo metabolism by host tyrosine hydroxylase, producing α-fluoromethyldopa, a metabolite likely to worsen Parkinson's phenotypes and prevent application as an l-dopa cotreatment. Here, we demonstrate oxidation of AFMT to α-fluoromethyldopa in vitro by recombinant human tyrosine hydroxylase. We then develop AFMT analogues that retain activity against bacterial decarboxylases but have reduced susceptibility to host hydroxylation. Suitable arenes for inhibitor design were identified using assays with commercially available noncanonical amino acids, which revealed aryl difluorination as a promising modification. Difluoroaryl AFMT derivatives are less prone to degradation by tyrosine hydroxylase in vitro yet still inhibit l-dopa metabolism by bacterial decarboxylases. This work exemplifies how substrate reactivity can streamline design of mechanism-based enzyme inhibitors, as well as how constraints posed by the host can be incorporated during development of microbiome-targeted therapeutics. The compounds reported here are promising starting points for future studies in animal models and further exploration of gut bacterial effects on l-dopa treatment efficacy.

Authors

Institutions

Publication Details

Journal
ACS Chemical Biology
Published
2026-11-18
DOI
https://doi.org/10.1021/acschembio.6c00480
Citations
1
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
2.62

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Inhibitors of Gut Bacterial l -Dopa Decarboxylation with Reduced Susceptibility to Host Metabolism

Vincent Nieto, C. Anders Olson, Jai Krishan Khurana, Rohan Narayan et al.
1 citations
ACS Chemical Biology
Parkinson's Disease Mechanisms and Treatments
2.62
article

Inhibitors of Gut Bacterial l -Dopa Decarboxylation with Reduced Susceptibility to Host Metabolism

Vincent Nieto, C. Anders Olson, Jai Krishan Khurana, Rohan Narayan, Emily P. Balskus, Peter James Turnbaugh, Chi "Chip" Le
article en
1 citations

Abstract

Microorganisms in the human gut influence the efficacy and metabolism of host-targeted small molecule therapeutics, including the frontline Parkinson's disease drug levodopa (l-dopa). Previous work has identified a mechanism-based inhibitor of gut bacterial decarboxylases that degrade l-dopa, α-fluoromethyltyrosine (AFMT). However, early experiments with AFMT in rodent models suggested undesirable in vivo metabolism by host tyrosine hydroxylase, producing α-fluoromethyldopa, a metabolite likely to worsen Parkinson's phenotypes and prevent application as an l-dopa cotreatment. Here, we demonstrate oxidation of AFMT to α-fluoromethyldopa in vitro by recombinant human tyrosine hydroxylase. We then develop AFMT analogues that retain activity against bacterial decarboxylases but have reduced susceptibility to host hydroxylation. Suitable arenes for inhibitor design were identified using assays with commercially available noncanonical amino acids, which revealed aryl difluorination as a promising modification. Difluoroaryl AFMT derivatives are less prone to degradation by tyrosine hydroxylase in vitro yet still inhibit l-dopa metabolism by bacterial decarboxylases. This work exemplifies how substrate reactivity can streamline design of mechanism-based enzyme inhibitors, as well as how constraints posed by the host can be incorporated during development of microbiome-targeted therapeutics. The compounds reported here are promising starting points for future studies in animal models and further exploration of gut bacterial effects on l-dopa treatment efficacy.

ACS Chemical Biology
Harvard University (US), University of California, San Francisco (US), Chan Zuckerberg Biohub San Francisco (US)
Jane Coffin Childs Memorial Fund for Medical Research, Harvard University, Biocodex Microbiota Foundation
Good health and well-being
Openalex Percentile: Top 18%
Parkinson's Disease Mechanisms and Treatments
2.62
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon